<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Garapati K</submitter><funding>DBT/Wellcome Trust India Alliance entitled "Center for Rare Disease Diagnosis, Research, and Training"</funding><funding>DBT/Wellcome Trust India Alliance entitled “Center for Rare Disease Diagnosis, Research, and Training”</funding><funding>DBT/Wellcome Trust India Alliance</funding><funding>Wellcome Trust</funding><pagination>cwae076</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617596</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>34(11)</volume><pubmed_abstract>SRD5A3-CDG is a congenital disorder of glycosylation (CDG) resulting from pathogenic variants in SRD5A3 and follows an autosomal recessive inheritance pattern. The enzyme encoded by SRD5A3, polyprenal reductase, plays a crucial role in synthesizing lipid precursors essential for N-linked glycosylation. Despite insights from functional studies into its enzymatic function, there remains a gap in understanding global changes in patient cells. We sought to identify N-glycoproteomic and proteomic signatures specific to SRD5A3-CDG, potentially aiding in biomarker discovery and advancing our understanding of disease mechanisms. Using tandem mass tag (TMT)-based relative quantitation, we analyzed fibroblasts derived from five patients along with control fibroblasts. N-glycoproteomics analysis by l</pubmed_abstract><journal>Glycobiology</journal><pubmed_title>N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts.</pubmed_title><pmcid>PMC7617596</pmcid><funding_grant_id>IA/CRC/20/1/600002</funding_grant_id><pubmed_authors>Garapati K</pubmed_authors><pubmed_authors>Joshi N</pubmed_authors><pubmed_authors>Sabu S</pubmed_authors><pubmed_authors>Morava E</pubmed_authors><pubmed_authors>Preston G</pubmed_authors><pubmed_authors>Ranatunga W</pubmed_authors><pubmed_authors>Budhraja R</pubmed_authors><pubmed_authors>Pandey A</pubmed_authors><pubmed_authors>Kantautas KA</pubmed_authors><pubmed_authors>Perlstein EO</pubmed_authors><pubmed_authors>Kozicz T</pubmed_authors></additional><is_claimable>false</is_claimable><name>N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts.</name><description>SRD5A3-CDG is a congenital disorder of glycosylation (CDG) resulting from pathogenic variants in SRD5A3 and follows an autosomal recessive inheritance pattern. The enzyme encoded by SRD5A3, polyprenal reductase, plays a crucial role in synthesizing lipid precursors essential for N-linked glycosylation. Despite insights from functional studies into its enzymatic function, there remains a gap in understanding global changes in patient cells. We sought to identify N-glycoproteomic and proteomic signatures specific to SRD5A3-CDG, potentially aiding in biomarker discovery and advancing our understanding of disease mechanisms. Using tandem mass tag (TMT)-based relative quantitation, we analyzed fibroblasts derived from five patients along with control fibroblasts. N-glycoproteomics analysis by l</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-05-22T03:15:35.907Z</modification><creation>2025-07-12T03:04:38.139Z</creation></dates><accession>S-EPMC7617596</accession><cross_references><pubmed>39360848</pubmed><doi>10.1093/glycob/cwae076</doi></cross_references></HashMap>